Customized anti-idiotypic antibody services
Green Mountain Antibodies develops high-affinity, low cross-reactivity anti-idiotypic antibodies to support pharmacokinetic (PK), immunogenicity (ADA), and neutralizing assays from preclinical through clinical development. With more than 30 years of experience and a success rate above 98% we deliver custom monoclonal and polyclonal antibodies tailored to your therapeutic program.
What Are Anti-Idiotypic Antibodies?
Anti-idiotypic antibodies (anti-IDs) are antibodies raised against the unique antigen-binding site (idiotope) of another antibody or therapeutic. They are essential tools for:
- Pharmacokinetic assays (PK): measuring drug levels in serum or plasma.
- Immunogenicity (ADA) assays: detecting anti-drug antibodies.
- Neutralizing assays: distinguishing free versus bound drug.
- Regulatory submissions: providing validated critical reagents for Investigational New Drug (IND) and Biologics License Application (BLA) filings.
___________________________________________________________________________________________________________________________________________________________________________________
Types of anti-idiotypic antibodies
Explore More Services
- Mouse Monoclonal Antibodies: Hybridoma Development
- Repetitive Immunizations Multiple Sites (RIMMS)
- ELISA Assay Development
- Gator Analysis
Paratope-binding anti-IDs (Type I): Compete with the therapeutic’s target, useful for detecting free drug.
Idiotope-binding anti-IDs (Type II): Bind outside the antigen binding site, useful for detecting total drug.
Complex-recognizing anti-IDs (Type III): Detect the therapeutic antibody bound to its target, useful for mechanistic studies.
A similar strategy is employed for the development of anti-idiotypic polyclonal antibodies in either rabbits or goats. The animals are immunized with the therapeutic. Antisera is collected over the course of 6 months, with the first purification occurring during month 2. The antibody is affinity purified against the drug, followed by a depletion column against Hu IgG; yielding highly purified material against the target.
Both monoclonal and polyclonal projects can be run in tandem, providing a tool set of antibodies that can be used through pre-clinical and clinical trials.
Platforms and Formats
We offer multiple formats to match your program’s needs:
- Monoclonal antibodies: Mouse hybridoma development for high specificity.
- Polyclonal antibodies: Rabbit, goat, or other species for rapid generation and broader epitope coverage.
- Recombinant options: Sequence recovery and expression to ensure long-term reproducibility.
Project protocol and screening strategies are set to maximize diversity and affinity.
Support Through Pre-clinical & Clinical Trials
Over the last 15 years the introduction of immune therapies, which includes immuno-oncology, has greatly increased the need for custom anti-idiotypic antibody production. These therapies have changed the landscape of clinical trials and the drug pipeline. Over 500 monoclonal antibody targets have been investigated. The timeline from concept to clinic is now only one year. One out of 4 monoclonal therapies are receiving FDA approval, where one out of 8 small molecules receive the same result.
_____________________________________________________________________________________________________________________________________________________________________________________
Monoclonal Lead Generation and Discovery
In addition to anti-idiotypic projects, GMAb assists translational science groups in creating tool antibodies and monoclonals against biomarkers for discovery lead generation. Such projects require increased diversity, where maximizing the number of antibody candidates is very important. Our strategy is to cast a wide net and incorporate multiple strains of animals, targeted immunization protocols, such as RIMMS, and complex ELISA assay development.
Performance Benchmarks
- Success rate: >98% of projects deliver functional anti-IDs.
- Cross-reactivity: Typically <2% interference with total human IgG.
- Affinity: High-affinity clones suitable for sensitive PK/ADA assays.
- Assay readiness: Validated for ELISA, and ready to test on MSD and other bioanalytical platforms.
Deliverables
- Purified monoclonal or polyclonal antibodies
- Stable hybridoma or recombinant antibody sequences (if requested)
- Affinity and specificity characterization data
- Recommended assay pairing (capture vs detection antibody)
- Project Summary for regulatory submission
All antibodies, clones, and sequences are fully owned by our clients. Confidentiality agreements are standard.
Why Choose Green Mountain Antibodies
- Proven success: >98% success rate across hundreds of projects
- Faster timelines: Typical delivery in ~16 weeks
- Flexible formats: Monoclonal, polyclonal, recombinant options
- Assay expertise: Support for PK, ADA, and neutralizing assays
- Trusted partner: 30+ years serving biopharma and CROs globally
Frequently Asked Questions
Paratope anti-IDs bind the therapeutic’s active site and are best for detecting free drug. Idiotope anti-IDs bind other idiotypic regions and can detect total drug.
How long does anti-idiotypic antibody development take?
Most monoclonal anti-ID projects are completed in 12–16 weeks. Polyclonal antibody development projects provide pilot material in ~2.5 months.
Do I own the antibodies developed?
Yes. All hybridomas, sequences, and purified antibodies are fully transferred to the client. Yes. We provide technical documentation and antibodies for IND, BLA, and clinical assay requirements.
What assay formats do you support?
We deliver anti-IDs screened by ELISA and BLI. MSD and SPR can be confirmed by the customer or a bioanalytical partner.
Get Started
Partner with Green Mountain Antibodies to accelerate your therapeutic development with high-quality anti-idiotypic antibodies.
Contact us today to discuss your project or request a quote.